Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

At the conclusion of this educational activity, the participant should be able to:
1) Describe mode of action of efgartigimod, human IgG1 antibody Fc fragment engineered to reduce pathogenic IgG autoantibody levels
2) Explain how study was performed (methodology, participant sites, patient numbers)
3) Summarize the outcomes and occurrence of adverse events